Navigation Links
Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
Date:1/18/2013

to advance our rich pipeline of drug candidates."

Biscayne's lead GHRH antagonist is in preclinical development initially for the treatment of castrate-resistant prostate cancer (CRPC), a particularly lethal form of prostate cancer affecting 30,000 new patients each year in the US.  The GHRH antagonists work through a novel pathway that reduces the levels of hormones fueling the growth of tumors.  In animal studies, these antagonists have shown promising anti-tumor activity and were synergistic with chemotherapy.  The company believes that GHRH antagonists may have therapeutic potential in many other types of tumors, including breast, brain, lung, colon and skin.

Biscayne's lead GHRH agonists have demonstrated a unique capacity to repair the heart following ischemic injury, such as a heart attack, and are in preclinical development for the repair of damaged cardiac tissue.  GHRH agonists directly activate GHRH receptors in the heart, stimulating tissue healing through a variety of mechanisms.  GHRH agonists may represent a new class of therapy for cardiac conditions that presently afflict millions of patients worldwide.

In preclinical studies, GHRH agonists improved both cardiac structure and function and reduced myocardial infarct size and scarring, thereby reducing the chance of future heart failure.  Joshua M. Hare , MD, a scientific co-founder of Biscayne, who is the Louis Lemberg Professor of Medicine in the University of Miami Health System, is working with Dr. Schally to develop the GHRH technology for coronary heart disease.Dr. Hare noted, "Despite the many advances in cardiovascular therapy, millions of patients are disabled and ultimately killed each year from cardiac damage due to coronary heart disease.  Our GHRH agonists represent a unique and powerful approach aimed at developing drugs to reduce and repair this damage.  I look forward to working with the Biscayne
'/>"/>

SOURCE Biscayne Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
2. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
3. Rafarma Pharmaceuticals, Inc. Achieves Full Certification
4. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
5. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
6. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
9. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Smith & Nephew (LSE:SN, NYSE: SNN ... its entry into the forefoot market with the ... Comprised of three separate repair options, the HAT-TRICK ... and reconstruction, a metatarsal osteotomy guide, and a ... also known as hammer toe correction. ...
(Date:7/31/2014)... July 31, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... JOLLA, Calif. , July 30, 2014 ... ), a biopharmaceutical company leading the discovery and development ... will report financial results and highlights for the quarter ... after the U.S. financial markets close. ... Wednesday, August 6, 2014, at 5:00 pm Eastern Daylight ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... N.Y., June 25 Lixte,Biotechnology Holdings (OTC Bulletin ... Neurological Disorders and Stroke (NINDS), National,Institutes of Health ... Research and Development Agreement (CRADA) to develop,drugs for ... in March,2006 was extended through September 2009., ...
... MichBio announced that,Johnson & Johnson Vice Chairman, Christine A. ... and Conference November 18-19 in Novi,Michigan. MichBio is the ... is the state,s premier life science event attracting,more than ... is one of the most respected professionals in the ...
... titled “Avanta AC™ Advanced Ceramics Solutions as ... white paper outlines the challenges in manufacturing ... as well as the advantages of SACHEM’s ... are critical to a variety of leading ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3Christine Poon Will Keynote MichBio Expo 2Christine Poon Will Keynote MichBio Expo 3 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
(Date:7/30/2014)... The San Antonio Life Sciences Institute (SALSI), a joint ... (UTSA) and The University of Texas Health Science Center ... Postdoc Initiative Pilot Program. The winners, Emily Boice from ... will receive $25,000 for their project titled, "Novel engineered ... post-ischemic environment." , Boice and Huang,s research is focused ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... 2013 The Damon Runyon Cancer Research Foundation ... its spring 2013 Clinical Investigator Award Committee review. ... are outstanding early career physician-scientists conducting patient-oriented cancer ... of the nation,s leading scientists and clinicians. ...
... other conditions caused by malfunctions in the body,s nerve ... treat. The problem is that one medicine may help ... which drugs will work with individual patients may be ... seemingly identical neurons can behave the same even though ...
... discovered a mechanism that triggers chronic inflammation in ... today in Nature Immunology , suggest a ... the way to a new class of therapies ... diseases without crippling the immune system. Alzheimer,s, atherosclerosis ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 2Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 3Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 4Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 5Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 6Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 7Nerve cells can work in different ways with same result 2Researchers discover new way to block inflammation 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: